KDR and neoplasm: An earlier establishment of Sunitinib in the breast cancer model presented marked reduction of tumor lymphatic and blood vessels density, as well as decreased axillary lymph nodes invasion, suggesting a prosperous blockade of LEC cellular function by dampening VEGFR-2/-3 activation from VEGF-C/-D (54).